We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
-12.38%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$12.1B
AUM Growth
-$2.55B
(-17%)
Cap. Flow
-$469M
Cap. Flow
% of AUM
-3.86%
Top 10 Holdings %
Top 10 Hldgs %
25.18%
Holding
858
New
52
Increased
315
Reduced
272
Closed
83
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$38.7M |
| 2 |
Apple
AAPL
|
+$27.7M |
| 3 |
Salesforce
CRM
|
+$26.1M |
| 4 |
Verizon
VZ
|
+$25.9M |
| 5 |
PepsiCo
PEP
|
+$24.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$65.7M |
| 2 |
Waste Management
WM
|
+$64.8M |
| 3 |
Sociedad Química y Minera de Chile
SQM
|
+$58.6M |
| 4 |
Citigroup
C
|
+$56.5M |
| 5 |
Johnson & Johnson
JNJ
|
+$41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.24% |
| 2 | Technology | 24.24% |
| 3 | Financials | 8.36% |
| 4 | Communication Services | 6.82% |
| 5 | Industrials | 6.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Boston Scientific
BSX
$67.6B
| $8.28M | 0.07% |
222,215
+146,361
| +193% | +$5.96M |
|
252
Okta
OKTA
$23.9B
| $8.26M | 0.07% |
91,356
+53,942
| +144% | +$5.83M |
|
253
TJX Companies
TJX
$173B
| $8.26M | 0.07% |
147,836
-484,239
| -77% | -$29.3M |
|
254
Copart
CPRT
$27.6B
| $8.19M | 0.07% |
301,504
+58,876
| +24% | +$1.68M |
|
255
PTC Therapeutics
PTCT
$6.29B
| $8.12M | 0.07% |
202,652
-70,722
| -26% | -$2.48M |
|
|
ACC
256
DELISTED
American Campus Communities, Inc.
ACC
| $8.09M | 0.07% |
125,501
+71,686
| +133% | +$4.54M |
|
257
Quest Diagnostics
DGX
$25.6B
| $8.06M | 0.07% |
60,646
+19,970
| +49% | +$2.72M |
|
258
Aflac
AFL
$64.4B
| $8.06M | 0.07% |
145,637
-106,417
| -42% | -$6.28M |
|
259
Kura Oncology
KURA
$901M
| $8.03M | 0.07% |
438,315
| – | – |
|
260
Ecopetrol
EC
$32.5B
| $7.96M | 0.07% |
733,400
-655,600
| -47% | -$10.4M |
|
261
Celldex Therapeutics
CLDX
$2.8B
| $7.84M | 0.06% |
290,794
+13,313
| +5% | +$387K |
|
262
Southern Copper
SCCO
$141B
| $7.83M | 0.06% |
169,574
-467,945
| -73% | -$27M |
|
263
Walmart Inc
WMT
$889B
| $7.74M | 0.06% |
190,908
+152,640
| +399% | +$7.04M |
|
264
Jack Henry & Associates
JKHY
$10.9B
| $7.58M | 0.06% |
42,131
+3,637
| +9% | +$681K |
|
265
Pacira BioSciences
PCRX
$1.04B
| $7.57M | 0.06% |
129,901
-44,180
| -25% | -$2.89M |
|
266
ResMed
RMD
$29.5B
| $7.55M | 0.06% |
35,998
-6,897
| -16% | -$1.47M |
|
267
Veracyte
VCYT
$4.44B
| $7.54M | 0.06% |
378,663
| – | – |
|
|
MORF
268
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $7.49M | 0.06% |
344,933
+160,537
| +87% | +$4.48M |
|
|
MTOR
269
DELISTED
MERITOR, Inc.
MTOR
| $7.35M | 0.06% |
202,379
-71,995
| -26% | -$2.59M |
|
270
Tandem Diabetes Care
TNDM
$1.18B
| $7.34M | 0.06% |
124,074
+81,499
| +191% | +$6.69M |
|
271
Intellia Therapeutics
NTLA
$1.49B
| $7.31M | 0.06% |
141,275
+40,148
| +40% | +$2.04M |
|
272
Jefferies Financial Group
JEF
$13B
| $7.24M | 0.06% |
274,253
+256,446
| +1,440% | +$7.58M |
|
|
CDK
273
DELISTED
CDK Global, Inc.
CDK
| $7.24M | 0.06% |
+132,212
| New | +$7.15M |
|
274
Everest Group
EG
$15.4B
| $7.19M | 0.06% |
25,646
+19,528
| +319% | +$5.52M |
|
275
Exelon
EXC
$48.2B
| $7.1M | 0.06% |
156,677
+17,368
| +12% | +$817K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2022 Portfolio in Review
As of Q2 2022, Candriam SCA held 858 positions worth $12.1B, down 17% from $14.7B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Candriam SCA withdrew a net $469M in Q2 2022, closing 83 positions and reducing 272 holdings. Its most notable exit was TriState Capital Holdings, Inc., an estimated $20.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 29% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Tenable Holdings worth $16.3M.
- Candriam SCA's largest Q2 2022 buy was Tenable Holdings: 359,981 shares worth $16.3M.
- Candriam SCA added most to Procter & Gamble in Q2 2022, an estimated $38.7M increase.
- Candriam SCA's biggest Q2 2022 reduction was Microsoft, cutting an estimated $65.7M.
- Candriam SCA fully exited TriState Capital Holdings, Inc. in Q2 2022, selling an estimated $20.9M.
- Candriam SCA's ten largest holdings make up 25% of its $12.1B portfolio in Q2 2022.
- Candriam SCA opened 52 new positions and closed 83 in Q2 2022.
- Candriam SCA's portfolio value fell 17% quarter-over-quarter to $12.1B.
Based on Candriam SCA's 13F filing for Q2 2022, filed 3 Aug 2022.